The genetic basis of haemophagocytic lymphohistiocytosis (HLH) has not been elucidated in 10% of affected patients. In this study, we report four HLH episodes in three patients with HAX1 gene mutations. We screened the mutations associated with congenital neutropenia (CN) because the neutropenia persisted following HLH treatment. There were homozygous HAX1 mutations detected in all patients. This is the first case series of patients with CN caused by HAX1 mutation who presented with HLH. We hypothesize that severe neutropenia persists after an HLH episode in children without HLH mutations (especially infants) because these patients have CN caused by HAX1 mutations.
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Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition characterized by specific clinical and laboratory abnormalities and defined by bone marrow biopsy evidence of haemophagocytosis . HLH is a clinical manifestation of several different disease entities that include both familial HLH (FHLH) and secondary forms. FHLH is caused by mutations in the perforin 1 gene (PRF1) or other genes regulating the exocytosis of cytotoxic granules . However, the genetic basis of the disease has not been elucidated in 10% of affected patients .
Congenital neutropenia (CN) is a genetically heterogeneous disorder characterized by life-long severe neutropenia and associated with severe recurring bacterial infections. Mutations in the neutrophil elastase gene (ELANE) and haematopoietic cell-specific Lyn substrate 1 (HCLS1) associated protein X-1 (HAX1) gene are present in approximately 60% and 30% of CN patients, respectively (Palmblad & Papadaki, 2008) .
In this study, we describe four HLH episodes in three patients with HAX1 gene mutations.
Patients and methods
All patients in this study met at least five of eight Histiocyte Society diagnostic criteria for HLH . The HLH-2004 treatment protocol includes steroids, ciclosporin A, etoposide and intrathecal methotrexate in selected patients, and stem cell transplantation. Following 8 weeks of initial therapy, all children with FHLH as well as children with a non-familial disease that is severe and persistent, or reactivated, continue with etoposide/steroids combination with ciclosporin A. For children with secondary HLH, the underlying cause of immune activation was treated first. If necessary, chemo-immunotherapy was also administered according to the protocol . Diagnostic criteria of HLH compared to features of the patients' episodes are shown in Table I . These patients were treated using the HLH-2004 protocol. Clinical and bone marrow aspiration findings are listed in Table II. DNA was isolated from a 200-ll peripheral blood sample using the QIAamp DNA blood Mini QIcube Kit with a QIcube instrument (QIAGEN, Hilden, Germany) according to the manufacturer's specifications. The entire coding sequence (exon 1-7) and intron-exon boundaries of the HAX1 gene were amplified by polymerase chain reaction (PCR) and sequenced on Illumina MiSeq NGS System (Illumina Inc., San Diego, CA, USA) using 300-cycle Reagent Kit V2. Base-calling and sequence alignment was performed using the built in MiSeq Reporter Software ( _ Illumina Inc., San Diego, CA, USA). Sequencing data was analysed using the Intergrative Genomics Viewer (Thorvaldsd ottir et al, 2013) . Mutations detected by next generation sequencing analysis were verified by Sanger sequencing on an ABI PRISM 3130 DNA analyser (Applied Biosystems, Foster City, CA, USA) using the Big Dye Terminator Cycle Sequencing V3.1 Ready Reaction Kit (Life Technologies, Carlsbad, CA, USA).
Patient 1
A 7-month-old male presented with a high fever and cervical lymphadenopathy. This was the patient's first hospitalization and his symptoms fulfilled six of the eight criteria for HLH (Patient 1, Episode 1, Table I ). The patient was treated with antibiotics, intravenous immunoglobulin (IVIG) and the HLH-2004 protocol. The test results for the PRF1, STX11 and UNC13D gene mutations were negative. His clinical situation resolved and the treatment was stopped after 8 weeks of initial therapy; because the severe neutropenia persisted, granulocyte-colony stimulating factor (G-CSF) (5 lg/kg) was started during week 5 of this episode and was stopped after the initial treatment. When the child was 15 months old, he experienced a second HLH episode caused by a varicella infection (Patient 1, Episode 2, Tables I, II). The HLH protocol, antibiotics, IVIG, G-CSF and acyclovir treatments were started. The HLH protocol was continued for 40 weeks and G-CSF treatment was continued for the persistent severe neutropenia. The persistent neutropenia was considered unusual and the patient was screened for common CN mutations: homozygous c.130-131 ins A (pW44X) HAX1 gene mutations were found. The patient has subsequently used G-CSF for more than 6 years (2 lg/kg/day, twice a week), and no additional HLH episodes have occurred. His clinical situation resolved and the treatment was stopped after 8 weeks of initial therapy. However, severe neutropenia persisted, requiring G-CSF treatment after 13 weeks following the detection of the HLH episode. G-CSF was used intermittently for more than 1 year. The patient was screened for common CN mutations and was found to be homozygous for the HAX1 mutation (pW44X). The patient has continued with G-CSF treatment (3 lg/kg/day, twice a week) for more than 5 years. No additional HLH episodes have occurred.
Patient 3
A 19-month-old female was admitted to the hospital with fever and cervical lymphadenopathy. HLH was considered as diagnosis (Table I ). The patient was treated with the HLH-2004 protocol. However, severe sepsis occurred at the end of week 6 while she had severe neutropenia. Immunosuppressive treatment was discontinued and G-CSF treatment was initiated. The patient subsequently recovered and was followed as an outpatient. Functional analyses found normal expression of perforin in natural killer (NK) cells, normal degranulation of NK cells and normal expression of HLA-DR on T cells. No mutations were observed in PRF1 and STX11. Although all laboratory and clinical findings attributable to FHLH disappeared, her absolute neutrophil count remained persistently low. We evaluated the mutational status of the CN and found a homozygous HAX1 mutation (pW44X). The patient was treated with G-CSF and responded well. The child has been receiving G-CSF treatment for 3 years and no infections have occurred.
Results and discussion
This study investigated four HLH episodes in three patients with HAX1 gene mutations. All patients were born from consanguineous marriages and all presented with a HLH episode preceding the diagnosis of CN. From early infancy, patients who have CN suffer from bacterial infections that may induce HLH. However, the patients reported here did not display clinical features of a severe life-threatening infection that may readily be expected in patients with CN. However, they fulfilled the diagnostic criteria for HLH at presentation. In fact, all patients responded to HLH-specific therapy accompanied by supportive treatment. Serum ferritin levels were not very high in our patients. Serum ferritin levels were lower than 1000 lg/l in 3 of the 4 HLH episodes. This result is unusual for HLH . However, Bode et al (2015) reported that 19 of the 63 patients with primary immunodeficiency and HLH had serum ferritin levels lower than 1000 lg/l.
Acute Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections were diagnosed by viral serological tests (anti-viral capsid antigen IgM and anti-CMV IgM positivity) because no PCR tests for EBV and CMV were available at that time. This was a limiting factor for our study.
The functions of HAX1 and its mechanism of action have not been fully elucidated. The protein is implicated in the regulation of several vital cellular processes, including apoptosis, cell migration, calcium homeostasis and mRNA regulation (Germeshausen et al, 2008; Zayat et al, 2015) . HAX1 encodes the HCLS1-associated protein X-1, a mitochondrion-associated anti-apoptotic protein that is critical for maintaining the inner mitochondrial membrane potential and protecting myeloid cells from apoptosis (Klein et al, 2007) . A recent study (Skokowa et al, 2012) demonstrated that interaction between HAX1, HCLS1, and the transcription factor lymphoid-enhancer-binding factor 1 (LEF1) plays an essential role in G-CSF-mediated granulopoiesis. G-CSF stimulates HCLS1 phosphorylation and binding to LEF1. Mutations in the HAX1 gene severely diminish the function of HCLS1. Additionally, patients with HAX1 mutations have profound down regulation of LEF1. LEF1 activates CCAAT/ enhancer binding protein alpha, which is a critical transcription factor for granulopoiesis (Skokowa et al, 2012; Skokowa & Welte, 2013) . LEF1 also binds to a functionally important site in the T-cell receptor-a (TCR-a) enhancer and confers maximal enhancer activity (Bruhn et al, 1997) . Thus, it can be speculated that there may be a relationship between HAX1 mutations and HLH caused by the down-regulation of LEF1, dysfunction of TCR-a and immunodeficiency.
The most common mutation of HAX1 is pW44X in CN patients of Middle-Eastern countries (Zeidler et al, 2009 ). The Turkish National Congenital Neutropenia Registry includes 152 patients with CN, 46 of who had HAX1 mutations (Yılmaz Karapınar et al, 2015) . Forty-three of these 46 cases had pW44X point mutations identical to the mutations detected in our cases. However, none of the patients from the registry were reported as having suffered an HLH episode. To our knowledge, there has been no case reported in the literature indicating a relationship between HAX1 mutation and HLH. This is the first case series of patients with CN caused by HAX1 mutation who presented with HLH. We hypothesize that severe neutropenia persists after an HLH episode in children without FHLH mutations (especially infants) because these patients have CN caused by HAX1 mutations.
